Sofía López
A5088480315- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- SARS-CoV-2 detection and testing
- Health and Medical Education
- Public Health and Environmental Issues
Pontificia Universidad Católica de Chile
2022
BackgroundThe Omicron variant has challenged the control of COVID-19 pandemic due to its immuno-evasive properties. The administration a booster dose SARS-CoV-2 vaccine showed positive effects in immunogenicity against SARS-CoV-2, effect that is even enhanced after second booster.MethodsDuring phase-3 clinical trial, we evaluated CoronaVac®, an inactivated administered 6 months first booster, neutralization (n = 87). In parallel, cellular immunity 45) was analyzed stimulated peripheral...
Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac®, an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity, preventing severe cases. We investigate non-inferiority of two immunization schedules CoronaVac® in a trial healthy adults. A total 2302 adults were enrolled at 8 centers Chile randomly assigned vaccination schedules, receiving doses with either 14 or 28 days between each. The primary efficacy endpoints solicited adverse events...
During the COVID-19 pandemic, importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes safety CoronaVac® in and adolescents between 3- 17-years-old a multicenter Chile with two vaccine doses 4-week interval. For all participants, immediate adverse events (AEs), serious AEs (SAEs), special interest (AESIs) were registered throughout study. In subgroup, recorded 28 days after each dose. surveillance performed A total 1139 individuals received first...
Abstract Background Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac ® (Sinovac Life Sciences), an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity in previous studies, preventing severe cases. We further investigated efficacy of two immunization schedules a non-inferiority trial healthy adults. Methods This is multi-center randomized clinical trial. Healthy adults were enrolled at eight centers Chile. Participants randomly assigned...
Introducción: La introducción progresiva de vacunas contra SARS-CoV-2 a partir 2021, priorizando grupos mayor edad, podrÃa implicar un cambio en el perfil pacientes hospitalizados por COVID-19 tiempo.